Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Relapse after HSCT 2021 | The efficacy of ATO and ATRA for APL

Mark Levis • 30 Sep 2021
Relapse after HSCT 2021
Acute Promyelocytic Leukemia Leukemia Rare Diseases All-trans retinoic acid Arsenic trioxide
APL0406

Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the APL0406 clinical trial (NCT00482833) that led to the approval of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) without chemotherapy for the treatment of acute promyelocytic leukemia (APL). This trial demonstrated that patients treated only with ATO+ATRA experienced long-term survival rates between 95-100%. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals